These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 16814521)
1. Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy. Specchio LM; Gambardella A; Giallonardo AT; Michelucci R; Specchio N; Boero G; La Neve A Epilepsy Res; 2006 Sep; 71(1):32-9. PubMed ID: 16814521 [TBL] [Abstract][Full Text] [Related]
2. Effects of levetiracetam on EEG abnormalities in juvenile myoclonic epilepsy. Specchio N; Boero G; Michelucci R; Gambardella A; Giallonardo AT; Fattouch J; Di Bonaventura C; de Palo A; Ladogana M; Lamberti P; Vigevano F; La Neve A; Specchio LM Epilepsia; 2008 Apr; 49(4):663-9. PubMed ID: 18266754 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study. Beran RG; Berkovic SF; Black AB; Danta G; Hiersemenzel R; Schapel GJ; Vajda FJ Epilepsy Res; 2005 Jan; 63(1):1-9. PubMed ID: 15716083 [TBL] [Abstract][Full Text] [Related]
4. Levetiracetam in juvenile myoclonic epilepsy: long-term efficacy in newly diagnosed adolescents. Verrotti A; Cerminara C; Coppola G; Franzoni E; Parisi P; Iannetti P; Aloisi P; Tozzi E; Cusmai R; Vigevano F; Chiarelli F; Curatolo P Dev Med Child Neurol; 2008 Jan; 50(1):29-32. PubMed ID: 18173626 [TBL] [Abstract][Full Text] [Related]
5. Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies. Rosenfeld WE; Benbadis S; Edrich P; Tassinari CA; Hirsch E Epilepsy Res; 2009 Jul; 85(1):72-80. PubMed ID: 19327967 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Kothare SV; Valencia I; Khurana DS; Hardison H; Melvin JJ; Legido A Epileptic Disord; 2004 Dec; 6(4):267-70. PubMed ID: 15634623 [TBL] [Abstract][Full Text] [Related]
7. Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study. Callenbach PM; Arts WF; ten Houten R; Augustijn P; Gunning WB; Peeters EA; Weber AM; Stroink H; Geerts Y; Geerts AT; Brouwer OF Eur J Paediatr Neurol; 2008 Jul; 12(4):321-7. PubMed ID: 17950011 [TBL] [Abstract][Full Text] [Related]
8. Clinical experience with levetiracetam in idiopathic generalized epilepsy according to different syndrome subtypes. Di Bonaventura C; Fattouch J; Mari F; Egeo G; Vaudano AE; Prencipe M; Manfredi M; Giallonardo AT Epileptic Disord; 2005 Sep; 7(3):231-5. PubMed ID: 16162433 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of levetiracetam: a review of three pivotal clinical trials. Privitera M Epilepsia; 2001; 42 Suppl 4():31-5. PubMed ID: 11564123 [TBL] [Abstract][Full Text] [Related]
10. Levetiracetam: a long-term follow-up study of efficacy and safety. Bauer J; Ben-Menachem E; Krämer G; Fryze W; Da Silva S; Kasteleijn-Nolst Trenité DG Acta Neurol Scand; 2006 Sep; 114(3):169-76. PubMed ID: 16911344 [TBL] [Abstract][Full Text] [Related]
11. Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study. Delanty N; Jones J; Tonner F Epilepsia; 2012 Jan; 53(1):111-9. PubMed ID: 22050371 [TBL] [Abstract][Full Text] [Related]
12. Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy. Prasad A; Kuzniecky RI; Knowlton RC; Welty TE; Martin RC; Mendez M; Faught RE Arch Neurol; 2003 Aug; 60(8):1100-5. PubMed ID: 12925366 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of levetiracetam in the treatment of drug-resistant Rett syndrome. Specchio N; Balestri M; Striano P; Cilio MR; Nardello R; Patanè S; Margiotta ML; D'Orsi G; Striano S; Russo S; Specchio LM; Cusmai R; Fusco L; Vigevano F Epilepsy Res; 2010 Feb; 88(2-3):112-7. PubMed ID: 19914805 [TBL] [Abstract][Full Text] [Related]
14. Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy. Coppola G; Mangano S; Tortorella G; Pelliccia A; Fels A; Romano A; Nardello R; Habetswallner F; Licciardi F; Operto FF; Pascotto A Epilepsy Res; 2004 Mar; 59(1):35-42. PubMed ID: 15135165 [TBL] [Abstract][Full Text] [Related]
16. Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate. Fountain NB; Conry JA; Rodríguez-Leyva I; Gutierrez-Moctezuma J; Salas E; Coupez R; Stockis A; Lu ZS Epilepsy Res; 2007 Apr; 74(1):60-9. PubMed ID: 17270398 [TBL] [Abstract][Full Text] [Related]
17. Levetiracetam in absence epilepsy. Verrotti A; Cerminara C; Domizio S; Mohn A; Franzoni E; Coppola G; Zamponi N; Parisi P; Iannetti P; Curatolo P Dev Med Child Neurol; 2008 Nov; 50(11):850-3. PubMed ID: 18808424 [TBL] [Abstract][Full Text] [Related]
18. Long-lasting antiepileptic effects of levetiracetam against epileptic seizures in the spontaneously epileptic rat (SER): differentiation of levetiracetam from conventional antiepileptic drugs. Ji-qun C; Ishihara K; Nagayama T; Serikawa T; Sasa M Epilepsia; 2005 Sep; 46(9):1362-70. PubMed ID: 16146430 [TBL] [Abstract][Full Text] [Related]
19. Levetiracetam in the treatment of Lennox-Gastaut syndrome. De Los Reyes EC; Sharp GB; Williams JP; Hale SE Pediatr Neurol; 2004 Apr; 30(4):254-6. PubMed ID: 15087103 [TBL] [Abstract][Full Text] [Related]